About the Authors
- Naama Dror
-
Affiliation Department of Cellular and Developmental Biology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
- Mathilda Mandel
-
Affiliation The Blood Center, Sheba Medical Center, Tel-Hashomer, Israel
- Gad Lavie
-
* E-mail: gad.lavie@sheba.health.gov.il
Affiliations Department of Cellular and Developmental Biology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, The Blood Center, Sheba Medical Center, Tel-Hashomer, Israel
Competing Interests
Gad Lavie has fiancial interest in Hy Biopjarma Ltd., a company that develops hypericin as an anti-cancer drug. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: ND GL MM. Performed the experiments: ND. Analyzed the data: GL ND MM. Contributed reagents/materials/analysis tools: GL. Wrote the paper: GL MM. Proposed directions in project: MM. Directed the project: GL.